Radiation oncology firm Elekta posted a wider net loss in financial results for its first quarter (end-July 31).
For the quarter, net sales decreased 4% to 1.865 billion Swedish kronor ($261 million U.S.), compared with 1.912 billion kronor ($267.7 million U.S.) in the same period last year. The company attributed the decline to slower than expected growth in mature markets, especially in the U.S.
The company had a net loss of 137 million kronor ($19.2 million U.S.), compared with a net loss of 8 million kronor ($1.1 million U.S.) for the same quarter last year.
